Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO).
作者： Benoit Rousseau , Arezki Khaled Boukerma , Julie Henriques , Romain Cohen , Olivier Lucidarme
DOI: 10.1200/JCO.2019.37.15_SUPPL.3121
关键词:
摘要: 3121Background: TEXCAN, a prospective phase II GERCOR study of treatment with REGO in chemorefractory metastatic colorectal cancer (mCRC) patients (NCT02699073) included pharmacokinet...
sci-hub.st 参考文章(0)